BRPI0209685B8 - derivado de peptídeo insulinotrópico e método para a produção de um derivado de peptídeo insulinotrópico - Google Patents
derivado de peptídeo insulinotrópico e método para a produção de um derivado de peptídeo insulinotrópicoInfo
- Publication number
- BRPI0209685B8 BRPI0209685B8 BRPI0209685A BR0209685A BRPI0209685B8 BR PI0209685 B8 BRPI0209685 B8 BR PI0209685B8 BR PI0209685 A BRPI0209685 A BR PI0209685A BR 0209685 A BR0209685 A BR 0209685A BR PI0209685 B8 BRPI0209685 B8 BR PI0209685B8
- Authority
- BR
- Brazil
- Prior art keywords
- insulinotropic peptide
- glu
- gly
- ser
- peptide derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"derivado de um peptídeo insulinotrópico e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método de produção de derivado de peptídeo insulinotrópico e uso de um derivado de peptídeo insulinotrópico e de sais farmaceuticamente aceitáveis". a presente invenção refere-se a derivados de um peptídeo insulinotrópico exendina-4 e sais farmaceuticamente aceitáveis produzidos dos mesmos, que são úteis para o tratamento da diabete do tipo ii. a exendina-4 apresenta uma estrutura química como mostrada abaixo: his-gly-glu-gly-thr-phe-thr-ser-asp-leu-ser-lys-gln-x-glu-glu-glu-ala-val-yleu-phe-ile-glu-trp-leu-lys-asn-gly-gly-pro-ser-ser-gly-ala-pro-pro-pro-ser-z na qual: x representa arg, leu ou ile, y representa his, arg ou lys e z representa arg-oh, -oh, -nh~ 2~ ou lys-oh. os derivados da presente invenção podem ser preparados por meios sintéticos químicos e, mais facilmente, por técnicas recombinantes, o que torna possível a produção comercial.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011128569A CN1162446C (zh) | 2001-05-10 | 2001-05-10 | 促胰岛素分泌肽衍生物 |
| PCT/CN2002/000316 WO2002090388A1 (fr) | 2001-05-10 | 2002-05-08 | Derives d'exendine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0209685A BR0209685A (pt) | 2004-07-13 |
| BRPI0209685B1 BRPI0209685B1 (pt) | 2016-03-01 |
| BRPI0209685B8 true BRPI0209685B8 (pt) | 2021-05-25 |
Family
ID=4659603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0209685A BRPI0209685B8 (pt) | 2001-05-10 | 2002-05-08 | derivado de peptídeo insulinotrópico e método para a produção de um derivado de peptídeo insulinotrópico |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7329646B2 (pt) |
| EP (2) | EP2223938B1 (pt) |
| JP (1) | JP4287153B2 (pt) |
| KR (1) | KR100902208B1 (pt) |
| CN (1) | CN1162446C (pt) |
| AU (1) | AU2002257497B2 (pt) |
| BR (1) | BRPI0209685B8 (pt) |
| CA (1) | CA2446394C (pt) |
| WO (1) | WO2002090388A1 (pt) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| CN1162446C (zh) * | 2001-05-10 | 2004-08-18 | 上海华谊生物技术有限公司 | 促胰岛素分泌肽衍生物 |
| EP1799710A2 (en) | 2004-10-07 | 2007-06-27 | Novo Nordisk A/S | Protracted glp-1 compounds |
| JP5107713B2 (ja) * | 2004-10-07 | 2012-12-26 | ノヴォ ノルディスク アー／エス | 遅延性のエキセンディン−４化合物 |
| CN100429227C (zh) * | 2005-06-29 | 2008-10-29 | 常州制药厂有限公司 | Exendin4多肽片段 |
| CN100374462C (zh) * | 2005-11-21 | 2008-03-12 | 大连帝恩生物工程有限公司 | 截短胰高血糖素样肽1(sGLP-1)、制法及其应用 |
| EP2035450A2 (en) * | 2006-05-26 | 2009-03-18 | Amylin Pharmaceuticals, Inc. | Composition and methods for treatment of congestive heart failure |
| CN102827284B (zh) | 2006-11-14 | 2015-07-29 | 上海仁会生物制药股份有限公司 | 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途 |
| LT3456340T (lt) * | 2007-01-08 | 2022-05-10 | The Trustees Of The University Of Pennsylvania | Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui |
| RU2413528C2 (ru) | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
| CN101040936B (zh) * | 2007-04-28 | 2011-10-19 | 大连水产学院 | 防治鱼类寄生虫病的复方中草药制剂 |
| CN101215324B (zh) * | 2007-12-26 | 2010-11-24 | 吉林大学 | 艾塞那肽短肽模拟肽及其在制备糖尿病治疗药物中的应用 |
| KR100864584B1 (ko) * | 2008-02-25 | 2008-10-24 | 성균관대학교산학협력단 | 비오틴으로 수식된 엑센딘 유도체, 이의 제조방법 및 이의용도 |
| CN101463078B (zh) * | 2009-01-12 | 2011-07-27 | 华东师范大学 | 一种Exendin-4衍生物及其固相化学合成 |
| CN101665799A (zh) * | 2009-06-29 | 2010-03-10 | 华东师范大学 | 一种Exendin-4衍生物的重组制备方法和应用 |
| WO2011063549A1 (zh) * | 2009-11-26 | 2011-06-03 | Wu Xiaoyan | 长效exendin4的类似物 |
| CN102397558B (zh) * | 2010-09-09 | 2013-08-14 | 中国人民解放军军事医学科学院毒物药物研究所 | Exendin-4类似物的定位聚乙二醇化修饰物及其用途 |
| CN102532301B (zh) * | 2010-12-31 | 2014-09-03 | 上海医药工业研究院 | 一类新型的Exendin-4类似物及其制备方法 |
| CN102718868A (zh) * | 2011-03-30 | 2012-10-10 | 上海华谊生物技术有限公司 | 定点单取代聚乙二醇化Exendin类似物及其制备方法 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| RU2652783C2 (ru) | 2012-12-21 | 2018-05-03 | Санофи | Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона |
| AU2014234400B2 (en) | 2013-03-21 | 2017-11-16 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| ES2624961T3 (es) | 2013-03-21 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Síntesis de productos de péptido que contienen imida cíclica |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2073856C (en) | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
| US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| DK144093D0 (pt) * | 1993-12-23 | 1993-12-23 | Novo Nordisk As | |
| US6265204B1 (en) * | 1997-01-17 | 2001-07-24 | Genencor International, Inc. | DNA sequences, vectors, and fusion polypeptides for secretion of polypeptides in filamentous fungi |
| DE69839021T3 (de) * | 1997-11-14 | 2013-08-08 | Amylin Pharmaceuticals, Llc | Neuartige exendin agonisten |
| BR9815670A (pt) * | 1997-11-14 | 2000-10-17 | Amylin Pharmaceuticals Inc | Compostos agonistas de exendina |
| US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
| EA003922B1 (ru) * | 1999-05-17 | 2003-10-30 | Конджачем, Инк. | Продолжительно действующие инсулинотропные пептиды |
| US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| AU2025401A (en) * | 1999-12-07 | 2001-06-18 | Yong-Hwa Lee | A bathtub for a pet dog |
| CN1162446C (zh) * | 2001-05-10 | 2004-08-18 | 上海华谊生物技术有限公司 | 促胰岛素分泌肽衍生物 |
| CN1363654A (zh) | 2001-07-19 | 2002-08-14 | 上海华谊生物技术有限公司 | 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法 |
-
2001
- 2001-05-10 CN CNB011128569A patent/CN1162446C/zh not_active Expired - Lifetime
-
2002
- 2002-05-08 CA CA2446394A patent/CA2446394C/en not_active Expired - Lifetime
- 2002-05-08 WO PCT/CN2002/000316 patent/WO2002090388A1/zh active Application Filing
- 2002-05-08 AU AU2002257497A patent/AU2002257497B2/en not_active Expired
- 2002-05-08 BR BRPI0209685A patent/BRPI0209685B8/pt not_active IP Right Cessation
- 2002-05-08 JP JP2002587464A patent/JP4287153B2/ja not_active Expired - Lifetime
- 2002-05-08 EP EP10001237.6A patent/EP2223938B1/en not_active Expired - Lifetime
- 2002-05-08 KR KR1020037014451A patent/KR100902208B1/ko active IP Right Grant
- 2002-05-08 EP EP02727167A patent/EP1386930A4/en not_active Withdrawn
-
2003
- 2003-11-07 US US10/704,409 patent/US7329646B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4287153B2 (ja) | 2009-07-01 |
| EP1386930A4 (en) | 2005-09-07 |
| CN1162446C (zh) | 2004-08-18 |
| US20040142866A1 (en) | 2004-07-22 |
| WO2002090388A1 (fr) | 2002-11-14 |
| BR0209685A (pt) | 2004-07-13 |
| EP1386930A1 (en) | 2004-02-04 |
| CN1363559A (zh) | 2002-08-14 |
| KR100902208B1 (ko) | 2009-06-11 |
| CA2446394C (en) | 2016-08-16 |
| JP2005502595A (ja) | 2005-01-27 |
| EP2223938B1 (en) | 2013-07-10 |
| US7329646B2 (en) | 2008-02-12 |
| AU2002257497B2 (en) | 2007-10-11 |
| CA2446394A1 (en) | 2002-11-14 |
| BRPI0209685B1 (pt) | 2016-03-01 |
| EP2223938A1 (en) | 2010-09-01 |
| KR20030094386A (ko) | 2003-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0209685B8 (pt) | derivado de peptídeo insulinotrópico e método para a produção de um derivado de peptídeo insulinotrópico | |
| JP6121992B2 (ja) | ポリペプチド | |
| TR200200252T2 (tr) | Şimerik polipeptidler, bunların üretimi için yöntem ve kullanımı | |
| CY1106774T1 (el) | Συνθεσεις φαρμακευτικων μεσων με βαση αλατα του τιοτροπιου και αλατα της σαλμετερολης | |
| BR112012014475A8 (pt) | derivados de glp-1 duplo-acilados. | |
| DK1877435T4 (da) | Glucagon-lignende-peptid-2 (glp-2)-analoger | |
| EA200700292A1 (ru) | Полипептиды с повышенной экспрессией | |
| BR0112538A (pt) | Sais estáveis de ácido o-acetilsalicìlico com aminoácidos básicos | |
| BR0007781A (pt) | Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf | |
| BRPI0114994B8 (pt) | composição de vacina | |
| BRPI0413276B8 (pt) | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica | |
| CY1106723T1 (el) | Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων | |
| CY1112241T1 (el) | Θραυσματα πεπτιδιου για διεγερση συνθεσης πρωτεϊνων εξωκυτταρικης μητρας | |
| ES2070919T3 (es) | Separacion cromatografica de las proteinas del plasma, principalmente del factor viii, del factor de willebrand de la fibronectina y del fibrinogeno. | |
| CR7938A (es) | Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico | |
| BR0211502A (pt) | Derivados de ácido acético de indano e seu uso como agentes farmacêuticos, intermediários, e método de preparação | |
| RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| BRPI0410760A (pt) | compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos | |
| WO2004027064A3 (en) | Ghrh analogues | |
| UY27491A1 (es) | Derivados de ácido acético | |
| PE20040797A1 (es) | Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion | |
| KR950032165A (ko) | 토코페롤 유도체 | |
| AR035077A1 (es) | Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos | |
| BRPI0209684B8 (pt) | derivado de magainina e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método para a produção do derivado de magainina e uso do derivado de magainina e sais farmaceuticamente aceitáveis | |
| BR0306878A (pt) | Peptìdeo não-agonista do receptor de fator de liberação de corticotropina 2, ácido nucleico e anticorpo isolados, composição farmacêutica e kit compreendendo o referido peptìdeo e uso do referido peptìdeo e ácido nucleico na fabricação de um medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: O MESMO DEVERA APRESENTAR CD UMA VEZ QUE O APRESENTADO NA PETICAO 18120031868 DE 27/08/2012 NAO POSSUI UMA SEQUENCIA GRAVADA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: SHANGHAI BENEMAE PHARMACEUTICAL COMPANY LIMITED (C |
|
| B25D | Requested change of name of applicant approved |
Owner name: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION (CN) |
|
| B25G | Requested change of headquarter approved |
Owner name: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION (CN) |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/03/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/05/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 08/05/2022 |